Since the use of PDX tumor models in preclinical studies can better recapitulate the tumor microenvironment and genetic heterogeneity observed in human cancers, we use a PDX model to evaluate the changes in PD-L1 expression by standard of care therapy. This evidence concerns the gene CD274 and neoplasm.